Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
InflaRx N.V. (IFRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/17/2025: IFRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $3.77
1 Year Target Price $3.77
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.33% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.52M USD | Price to earnings Ratio - | 1Y Target Price 3.77 |
Price to earnings Ratio - | 1Y Target Price 3.77 | ||
Volume (30-day avg) 7 | Beta 1.32 | 52 Weeks Range 0.71 - 2.81 | Updated Date 06/30/2025 |
52 Weeks Range 0.71 - 2.81 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.86 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -41252.01% |
Management Effectiveness
Return on Assets (TTM) -34.47% | Return on Equity (TTM) -54.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -20016164 | Price to Sales(TTM) 412.48 |
Enterprise Value -20016164 | Price to Sales(TTM) 412.48 | ||
Enterprise Value to Revenue 72.13 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 67747104 | Shares Floating 56940785 |
Shares Outstanding 67747104 | Shares Floating 56940785 | ||
Percent Insiders 6.44 | Percent Institutions 26.24 |
Analyst Ratings
Rating 3 | Target Price 3.77 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
InflaRx N.V.
Company Overview
History and Background
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-inflammatory therapeutics targeting the complement system. Founded in 2007, it has advanced several product candidates, including vilobelimab (IFX-1), through clinical trials.
Core Business Areas
- Drug Development: Discovery, research, and clinical development of monoclonal antibodies targeting the complement system to treat inflammatory diseases.
Leadership and Structure
The leadership team consists of experienced professionals in the biopharmaceutical industry, including a CEO, CFO, and Chief Medical Officer. The company operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- Vilobelimab (IFX-1): A first-in-class monoclonal anti-C5a antibody. Currently under development for several indications, including COVID-19 related ARDS, HS, and other inflammatory diseases. Market share data not currently available, as it awaits regulatory approval and commercial launch. Competitors include companies developing other complement inhibitors, such as Apellis Pharmaceuticals and Novartis, and anti-inflammatory drugs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, characterized by significant R&D investment, regulatory hurdles, and patent protection. Focus areas include immunology, oncology, and infectious diseases.
Positioning
InflaRx N.V. is positioned as a specialist in complement-targeted therapeutics, aiming to address unmet needs in inflammatory diseases with a novel approach.
Total Addressable Market (TAM)
The TAM for complement inhibitors in inflammatory diseases is estimated to be in the billions of dollars. InflaRx N.V. is positioned to capture a portion of this market with vilobelimab if approved.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Strong patent portfolio
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on single product candidate
- Dependence on regulatory approval
Opportunities
- Expansion into new indications
- Partnerships and collaborations
- Favorable regulatory environment
Threats
- Competition from established players
- Clinical trial failures
- Regulatory setbacks
Competitors and Market Share
Key Competitors
- APLS
- NVS
Competitive Landscape
InflaRx N.V. faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its novel therapeutic approach and specific focus on complement-targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and expanding product pipeline.
Future Projections: Future growth depends on the successful development and commercialization of vilobelimab.
Recent Initiatives: Recent initiatives include advancing clinical trials, seeking regulatory approval, and exploring partnerships.
Summary
InflaRx N.V. is a development-stage biopharmaceutical company focusing on complement-targeted therapies. Its success hinges on the clinical and regulatory progress of vilobelimab. While the company possesses a novel therapeutic approach, it faces competition from larger, more established players and relies on future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry databases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InflaRx N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-11-08 | Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.inflarx.de |
Full time employees 74 | Website https://www.inflarx.de | ||
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.